1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Novartis AG
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Any genitourinary disorders are noted in the urinary tract and the genital organs. The conditions in these parts of the human body could occur due to various bacterial infections or STDs. Genitourinary ailments also include various cardnomas such as prostate cancer, ovarian cancer, bladder cancer, and cervical cancer. The prevalence of these conditions is high worldwide and is continuously increasing. Lifestyle disorders such as stroke, autoimmune conditions such as multiple sclerosis, obesity, diabetes, or age-related ailments such as Alzheimer's are significantly responsible for genitourinary conditions. The prevalence of such health conditions is rising globally due to the sedentary lifestyle. Such a high prevalence of genitourinary diseases will drive the market growth during the forecast period. The analysts have predicted that the genitourinary drugs market will register a CAGR of almost 3% by 2023.
Market Overview
Technological advances in diagnostics
Advances in technology help in increasing patient adherence to treatment and gaining effective and swift results. They help in improving the condition of patients and reducing the diagnostic time. With the recent advances, both in the molecular laboratory diagnosis and point-of-care (POC) diagnostics technology, the vendors of the global genitourinary drugs market are also providing effective and quick results with less cost.
Patent expiries of novel drugs
Patent expiries of novel therapeutics lead to the introduction of generic drugs. Therefore, generic drugs are more cost-effective than novel therapeutics. Patents of many novel drugs used for the treatment of genitourinary conditions have expired, and a few of them are about to lapse during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the genitourinary drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Market Overview
Technological advances in diagnostics
Advances in technology help in increasing patient adherence to treatment and gaining effective and swift results. They help in improving the condition of patients and reducing the diagnostic time. With the recent advances, both in the molecular laboratory diagnosis and point-of-care (POC) diagnostics technology, the vendors of the global genitourinary drugs market are also providing effective and quick results with less cost.
Patent expiries of novel drugs
Patent expiries of novel therapeutics lead to the introduction of generic drugs. Therefore, generic drugs are more cost-effective than novel therapeutics. Patents of many novel drugs used for the treatment of genitourinary conditions have expired, and a few of them are about to lapse during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the genitourinary drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Novartis AG
PART 01: EXECUTIVE SUMMARYPART 06: PIPELINEPART 08: CUSTOMER LANDSCAPEPART 10: DECISION FRAMEWORKPART 12: MARKET TRENDS
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Novartis AG
Global Genitourinary Drugs Market 2019-2023
The analyst recognizes the following companies as the key players in the global genitourinary drugs market: Astellas Pharma Inc., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of biologics and gene theraphy.”
According to the report, one of the major drivers for this market is the rising geriatric population.
Further, the report states that one of the major factors hindering the growth of this market is the preference for substitute treatment options.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global genitourinary drugs market: Astellas Pharma Inc., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of biologics and gene theraphy.”
According to the report, one of the major drivers for this market is the rising geriatric population.
Further, the report states that one of the major factors hindering the growth of this market is the preference for substitute treatment options.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Novartis AG
Note: Product cover images may vary from those shown
